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fil, tadalafil, and the newest available agent, avanafil, appear to be equally effective, but tadalafil has a longer duration of action and avanafil has a more rapid onset [7, 8] . Since PDE-5 inhibitors are so commonly prescribed for ED, PDE-5 inhibitor use can be considered as a proxy for the diagnosis of ED and can be used as a way to measure the scope of this problem in men with IBD. Until now, sexual dysfunction in men with IBD has been difficult to measure and has been examined only in small case series or crosssectional questionnaire studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ; there have been no former studies that have compared the prevalence of ED in men with and without IBD. Most former studies have used a generic measure of sexual function, the Internal Index of Erectile Dysfunction (IIEF) and applied it to the field of IBD. The IIEF assesses erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction but it is a broad instrument and therefore lacks IBD-specific domains [19] . It cannot take into account the oftensevere signs and symptoms of IBD including abdominal pain, diarrhea, perianal disease, and/or life with an ostomy. Based on the IIEF, the prevalence of sexual dysfunction in men with IBD is reported to be anywhere from 10-50% [9] [10] [11] [12] .
These studies give us an indication that men with IBD have decreased sexual function but we still do not know the magnitude of the problem compared to the background population. In this study, we wish to examine the use of ED medications in men with IBD compared to men without IBD. We will use the Danish health registries that include all citizens in Denmark to study this issue in a large IBD population over a 22-year period.
MAtErIAlS And MEthodS

Setting
The Danish public healthcare system is tax financed and is free of charge for all residents, and this allows us to use a population-based study setting. Since 1968, each Danish resident is assigned to a unique registration number from the Danish Central Personal Registration system (CPR) [20] and hence each individual is uniquely identifiable. As all Danish registries use the unique civil registration number as an identifier, data can be linked unambiguously. Data from two other nationwide Danish health registries were used for this study: (i) the Danish National Patient Registry (NPR) [21] and (ii) The Danish National Prescription Registry (DNPR), maintained by the Danish Medicine Agency [22] . Using the unique civil registration number, data were linked to the CPR providing information on death and immigration on all individuals.
Medical data
Since 1 January 1995 the DNPR has recorded complete data on all drug prescriptions in Denmark. All pharmacies in Denmark use an automated system to send data on all outpatient drug prescriptions to the DNPR. The information transmitted from the pharmacies includes the patient's civil registration number, the type of drug prescribed according to the anatomical therapeutic chemical (ATC) classification system, and the date of the filled prescription. The DNPR however does not have information on overthe-counter medications, but in Denmark ED medications cannot be obtained from a pharmacy without a prescription. From the DNPR we obtained information on prescriptions for medications used to treat ED using the following drugs: alprostadil, sildenafil, tadalafil, vardenafil, avanafil, and aviptadil. Further information was obtained on prescriptions for intestinal anti-inflammatory agents for IBD (5-ASA agents, steroid enemas, or foam), and corticosteroids for systemic use. Of non-IBD medications which could possibly be related to ED we obtained prescriptions for: psychoanaleptics, antipsychotics, anxiolytics, sedative/hypnotics, antiepileptics, and opioids (please see Appendix for specific codes).
Study population, and exposed and unexposed cohorts
From the NPR, we identified the exposed for the study population according to the following requirements: (i) all males in Denmark diagnosed with Crohn's disease (CD) (ICD-8 codes: 563.01; ICD-10 codes K50) or ulcerative colitis (UC) (ICD-8 codes: 563.19; 569.04; ICD-10 codes: K51.0; K51.1; K51.2; K51.3) from 1 January 1977 until 31 December 2016 (ii) none of the men with IBD had an ED prescription prior to their first IBD diagnosis, and (iii) be at risk for ED prescription (≥18 years) within the study period of 1 January 1995 to 31 December 2016 (22-year study period). The study period was chosen to start on 1 January 1995, as this was the public market launch of sildenafil. We matched the exposed IBD males to unexposed males without IBD using risk-set sampling [23] . To each exposed male with IBD, we randomly assigned 10 age-matched unexposed males from the CPR without any IBD diagnosis in the NPR. The age matching was performed on birth year and month. Furthermore, the requirement for the unexposed were that they had to be alive and free of prior ED prescriptions when their corresponding exposed male became at risk. There were 55 men with UC or CD for which it was not possible to find ten controls as they were very old at the start of the study period or had incomplete data, and we therefore excluded those 55 men with IBD from the study population. The remaining exposed and unexposed men comprised our cohorts, and the first UC or CD diagnosis for each exposed is referred to as the index date for both the exposed and his assigned unexposed.
For the exposed cohort of men with IBD we identified those who had undergone IBD-related surgeries. The relevant surgeries for UC and CD were identified according to codes in the new and former version of the "Nordic Classification of Surgical Procedures" (please see Appendix for specific codes).
Outcome
We used this matched cohort study approach to study an ED prescription as an outcome. Our outcome was a first ED prescription.
Study analyses
Contingency tables and cross tabulations were constructed for the main study variables comparing the exposed and unexposed cohorts, and descriptive characteristics were given for the type of operations performed on men with IBD. Descriptive information was given for medication use within a period of 6 months before ED prescription. Both crude and adjusted multivariate Cox proportional hazard models were constructed to assess the association between IBD and the outcome of first ED prescription, and the hazard ratio (HR), including 95% confidence intervals (CI), was increased Use of Medications for erectile Dysfunction...
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The American Journal of GastroenteroloGy presented. In the adjusted model, we included operations relevant for CD or UC, central nervous system (CNS) medications (opioids, psychoanaleptics, anxiolytics, sedatives/hypnotics), intestinal anti-inflammatory medications, systemic corticosteroids, and Charlson comorbidity index score (0 [no comorbidity], 1, 2, ≥3) [24] . Specific ATC groups of medications were first evaluated separately in the model, but as they had only very little effect, one joined variable was constructed. All covariates were modeled as time-varying but only allowed to move irreversibly uni-directionally, so that a change in a variable could not switch back. In the statistical model, medications and operations relevant for CD and UC were considered from the start of the study period until the end of the study/censoring/ED prescription, whichever came first. The time under risk was individually set for each exposed and unexposed to start on the date of the most recent occurrence of either their index date, their 18th birthday, or 1 January 1995. Furthermore, analyses specifically on UC and CD were performed to elaborate their individual effect on the outcome.
To investigate the robustness of the models we also performed a sensitivity analysis using ≥2 ED prescriptions as the outcome.
In sub-analyses 1 and 2, we examined a possible confounding impact of the use of azathioprine, 6-mercaptourine, methotrexate (please see Appendix for specific codes), and biologic therapies (infliximab or adalimumab) (given in the NPR by procedure codes for all infusions/injections). Analysis of an impact of biologics was only performed in a sub-cohort as biologics have only been used since 2003. Cardiovascular diseases are part of the Charlson comorbidity index, but in sub-analysis 3 we examined the specific impact of cardiovascular diseases on our outcome.
All analyses were conducted using Stata 14.2 software (StataCorp LP, College Station, TX, USA).
Approvals and ethical considerations
The study was approved by the Danish Data Protection Agency (no. 2014-41-3466). According to Danish law, there are no ethical approvals of register-based studies.
rESultS
The exposed cohort of men with IBD comprised N = 31,498, and men without IBD comprised the unexposed cohort (N = 314,980). Within the exposed cohort, 21,966 (69.7%) men had UC while 9532 (30.3%) had CD. Characteristics for the exposed and unexposed cohorts are shown in Table 1 . For the exposed cohort, the median age (25-75% percentile) at index date was 39.7 (26.6-57.2) years and was naturally similar among unexposed (due to matching). Of the exposed men, 0.2% had reimbursed a prescription of intestinal anti-inflammatory medications or systemic corticosteroid medications 6 months before their first ED prescription. Use of opioids, antiepileptics, antipsychotics, anxiolytics, and psychoanaleptics in the period before ED prescription was rare ( Table 1) . The median duration in years from the index date until first ED prescription was quite similar between the groups, namely 10.7 (25-75% percentile: 4.8-18.9) for the exposed and 10.6 (25-75% percentile: 4.7-18.8) for the unexposed. However, the number of males who had their first Use of antiepileptics within 6 months before eD prescription Use of antipsychotics within 6 months before eD prescription Use of anxiolytics within 6 months before eD prescription ED prescription within the study period was 3749 (11.9%) for the exposed and 30,635 (9.7%) for the unexposed group. For the exposed men with IBD, 1189 (31.7%) were ≤50 years old at the time of first ED prescription, versus 8440 (27.6%) among unexposed; among exposed 2088 (55.7%) were 51-70 years old at their first ED prescription, versus 17,170 (56.0%) among unexposed; and among exposed 472 (12.6 %) were ≥71 years old at the time of first ED prescription versus 5025 (16.4%) among unexposed. In the exposed cohort 2138 (6.8%) had a cardiovascular disease (using all the diagnostic codes for cardiovascular diseases from the Charlson index) before end of follow-up, whereas for the unexposed cohort it was 16,085 (5.1%).
Operations
Among the 3749 men with IBD with a first ED prescription, there were 720 (19.2%) with at least one UC or CD relevant operation before the first ED prescription and most of these men had only one operation before the ED prescription ( Table 2 ).
In addition, we investigated the separate effect of CD and UC on ED prescription with and without an operation for IBD ( Table 2 ). The adjusted HR for men with UC and no prior UC operation was 1.17 (95% CI: 1.10-1.24), and for men with UC and a prior UC operation the adjusted HR was 1.43 (95% CI: 1.27-1.61). The corresponding adjusted HRs for men with CD were 1.26 (95% CI: 1.15-1.38) and 1.20 (95% CI: 1.06-1.35), respectively ( Table 3) .
Sensitivity analysis using second ED prescription as outcome
For the exposed cohort there were 2532 (8.0%), and for the unexposed cohort 20,420 (6.5%), males with at least two ED prescriptions within the study period. Using this outcome, the adjusted HR (95% CI) for the second ED prescription was 1.19 (95% CI: 1.12-1.28) for men with IBD and without IBD operations, and 1.35 (95% CI: 1.21-1.50) for men with IBD and a former IBD operation. We also stratified according to CD and UC and the results were similar to our main analyses (data not shown).
Sub-analyses
After inclusion of azathioprine/6-mercaptourine/methotrexate in the Cox regression model, the HR for prescription of ED in men with IBD relative to men without IBD remained unchanged. Also, including information on biologic therapies into the model did not change the results. When we adjusted specifically for 
dIScuSSIon
In this study, we show that men with UC and CD use ED medications more frequently than men without IBD, regardless of former IBD surgery. Most importantly, we were able to control for a number of confounders including medications that might influence sexual function: corticosteroids, psychoanaleptics, antipsychotics, anxiolytics, sedative/hypnotics, antiepileptics, and opioids. Use of biologics, azathioprine/6-mercaptourine/methotrexate had no impact on our results. Surgery for IBD that entails pelvic dissection, especially ileoanal pouch surgery and rectal resection can potentially cause damage to the autonomic nerves. In several small case-control or questionnaire studies, the effect of ileoanal pouch anastomosis or ileostomy surgery is mixed, with some men reporting better sexual function after surgery and some with no change or decreased function [15] [16] [17] [18] . In the only study that has used an IBD-specific screening tool to measure male sexual dysfunction in IBD, the authors found that, age >50, active CD, the presence of an ileostomy, and comorbid depression all contribute to impaired sexual function [25] . About a third of our UC patients had an IPAA or a rectal excision and about 8% of our CD patients had a full or partial rectal excision. Our results suggest that the highest risk for receiving an ED prescription is in men with UC who have had UC surgery. The numbers of our patients were too small to calculate if surgery that involved pelvic dissection versus surgery that did not involve pelvic dissection was more likely to cause patients to fill a prescription for an ED medication. If the rates of surgery are an indication of disease severity, the number of patients in our study who had an IBD operation prior to the end of follow-up (16.1% overall) is about that expected for a general IBD population in Denmark [26] .
Our study has several strengths. It is the first to examine the prevalence of ED in all men with IBD compared to age-matched men without IBD in a nationwide setting. Second, the nature of the Danish health registries allows a 22-year study period of observation, providing us with high statistical power. Third, this study includes all men ≥18 years with IBD and because we have full follow-up on all our cohorts and no dropouts, we had no selection bias. Our outcome measurement of ED prescription was made independent of the exposure assessment and of the hypothesis investigated, thereby preventing information bias. Fourth, we had valid data from the NPR and the DNPR [21, 22] . All patients with UC and CD were identified in the NPR, and the diagnosis was based on the hospital discharge diagnoses and specific codes for surgical procedures for UC and CD were obtained. The completeness of diagnoses of UC and CD have been examined in a Danish study using the pathology system as a reference standard-showing that among all patients, with a confirmed diagnosis of UC or CD, 94% were included in the NPR and the validity of the diagnoses of UC or CD was of very high quality with positive predictive values of 90 and 97%, respectively [27] . Fifth, we were able to analyze the impact of IBD surgery and several confounders on ED prescriptions.
Our study also has limitations. One limitation of examining prescriptions for ED medications as a proxy for sexual dysfunction is that some men with normal sexual function may use ED medications as a sexual enhancer. These men would probably be less likely to obtain a prescription from a physician but would rather obtain a supply from the internet. Asking a physician to fill an ED prescription implies that the patient had a real problem with sexual dysfunction and that the physician offered a prescription for an ED medication as a treatment. Also, a possible tendency to use an ED medication as a sexual enhancer would not bias our results as this would apply to men both in the exposed and unexposed cohorts. In addition, we performed a sensitivity analysis using a second ED prescription as an outcome. This helps us ensure that continued sexual dysfunction is the real reason for ED medication use and not a sporadic desire for sexual enhancement.
Additional factors such as age, testosterone use, and/or anabolic steroid use could affect use of ED medications. In our study, men with IBD received their first ED prescription at a younger age than men without IBD. However, for men <50 years in the exposed and unexposed cohorts, there was no difference in time from IBD diagnosis or index date to the first ED prescription. We had no data on testosterone or metabolic steroid use since we felt that both men with and without IBD may be getting an unknown quantity of supplements from health food stores or over the internet. In a future study of the predictors of sexual dysfunction, it would be helpful to measure testosterone levels in men with and without IBD. A low testosterone level might not only be associated with sexual dysfunction but also osteopenia and osteoporosis [28, 29] . Another limitation of our study is the inability to accurately measure IBD severity or activity, and in our study, we cannot distinguish whether sexual dysfunction is related to the IBD itself or associated factors. Disease activity may have a significant impact on libido, sexual function, level of sexual activity, and enjoyment of sex [10, 25, 30] . In a cross-sectional study of 280 male IBD patients, 67% of males with active IBD reported severe sexual compromise compared to 21% of patients in remission, and erectile and ejaculatory difficulties were associated with active disease [10] . However, IBD itself is a state of chronic inflammation with symptoms that wax and wane over time and it is possible that even when quiescent to mild, IBD may have a negative effect on sexual function. We could not adjust for smoking, a factor that has been associated with ED [31, 32] and also Crohn's disease [33] . Although theoretically, smoking may be a confounder in our study, no Danish health registries include information on smoking habits for men.
Also, we cannot rule out that patients with a chronic disease have more frequent interactions with healthcare providers and are more likely to be accepting of pharmacotherapy for other medical conditions including ED. Future studies should include men with other chronic, non-surgically treated health conditions to determine whether increased ED medication use is related specifically to IBD or if it is a consequence of more frequent doctor visits and/ or chronic disease in general.
Our study is the first to demonstrate that men with UC and CD are more likely to receive a prescription for an ED medication than men without IBD. Surgery for UC was associated with the highest HR of receiving an ED prescription. These results emphasize that physicians should make a concerted effort to screen for sexual dysfunction. In a recent study from O'Toole et al., 78% percent of male patients reported that they would feel comfortable talking to their doctor about sex, although only 10% reported their IBD provider initiating a conversation about sex [25] . Seventytwo percent had no preference for a male or female provider, and 22% would feel more comfortable talking to a male provider [25] . If a patient does have sexual dysfunction, there are a number of resources available. Patients can be evaluated and then treated for depression, increased disease activity and/or hypogonadism. Surgical risks can be discussed and then weighed against continuing medical treatment. Since only a small percentage of men with IBD discuss sexual dysfunction with their physician, our results probably underestimate the true scope of the problem. Physicians must start asking, and patients must start talking, about sexual dysfunction so its severe impact on quality of life can be alleviated.
